March 27, 2026
Navigator Medicines Advances NAV-240 into Phase 2a and NAV-242 into the Clinic, Supported by New Positive Data Presented at American Academy of Dermatology (AAD) Annual Meeting 2026
January 8, 2026
Navigator Medicines Accelerates Anti OX-40L and TNFα Bispecific Antibody Clinical Development Pipeline into Phase 2a and First-in-Human Trials
November 20, 2025
Navigator Medicines Completes Last Participant Last Visit (LPLV) in Phase 1b Trial of NAV-240, an OX40L and Anti-TNFα Bispecific Antibody for Autoimmune Disease
September 17, 2025
Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune Diseases
May 29, 2025
Navigator Medicines Announces First Participants Dosed in a Phase 1b Trial of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases
February 11, 2025
Navigator Medicines Appoints Tausif ‘Tosh’ Butt as Chief Executive Officer and Khurem Farooq as Chairman of the Board of Directors
August 27, 2024
Navigator Medicines Announces $100 Million Series A Financing and In-Licensing of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases
